|
| 35999168 | Moving Precision Oncology for Advanced Prostate Cancer from Theory to Practice. | Eur Urol Focus | 2023 |
| 37087376 | PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. | Eur Urol | 2023 |
| 37217634 | Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment. | Clin Transl Oncol | 2023 |
| 37284046 | Germline <i>ATM</i> Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer. | Eur Urol Open Sci | 2023 |
| 36972661 | Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. | Eur J Cancer | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36725142 | Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission. | Lancet Oncol | 2023 |
| 36529447 | Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. | Ann Oncol | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36043882 | Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. | Clin Cancer Res | 2023 |
| 34740923 | Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score. | Clin Cancer Res | 2022 |
| 35440717 | Delivering precision oncology to patients with cancer. | Nat Med | 2022 |
| 35820087 | Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. | JCO Precis Oncol | 2022 |
| 35425960 | Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. | Cancer Res | 2022 |
| 35657156 | Clinical implications of homologous recombination repair mutations in prostate cancer. | Prostate | 2022 |
| 36332173 | IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer. | JCO Glob Oncol | 2022 |
| 36267983 | Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease. | Front Oncol | 2022 |
| 35151155 | Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. | Cancer Treat Rev | 2022 |
| 35181943 | Diffusion MRI signal cumulants and hepatocyte microstructure at fixed diffusion time: Insights from simulations, 9.4T imaging, and histology. | Magn Reson Med | 2022 |
| 35091440 | Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). | Clin Cancer Res | 2022 |
| 34716049 | Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. | Eur Urol | 2022 |
| 32988971 | Characterizing CDK12-Mutated Prostate Cancers. | Clin Cancer Res | 2021 |
| 33494937 | Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. | Eur Urol | 2021 |
| 33742977 | Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies. | Curr Opin Urol | 2021 |
| 33626496 | Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. | Eur J Cancer | 2021 |
| 33497314 | A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. | Radiology | 2021 |
| 33630412 | Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. | J Pathol Clin Res | 2021 |
| 34411971 | Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. | ESMO Open | 2021 |
| 34045297 | Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. | Cancer Discov | 2021 |
| 34103179 | Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. | Eur Urol | 2021 |
| 34066080 | Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. | Cancers (Basel) | 2021 |
| 34256353 | PARP inhibitors in advanced prostate cancer: when to use them? | Endocr Relat Cancer | 2021 |
| 33059945 | Genetic counseling in prostate cancer: How to implement it in daily clinical practice? | Actas Urol Esp (Engl Ed) | 2021 |
| 33422353 | Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. | Eur Urol | 2021 |
| 33176972 | Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. | Eur Urol | 2021 |
| 32343890 | Olaparib for Metastatic Castration-Resistant Prostate Cancer. | N Engl J Med | 2020 |
| 34258585 | Accelerating precision medicine in metastatic prostate cancer. | Nat Cancer | 2020 |
| 31874108 | Genomics of lethal prostate cancer at diagnosis and castration resistance. | J Clin Invest | 2020 |
| 31806540 | Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. | Lancet Oncol | 2020 |
| 32853681 | Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. | Ann Oncol | 2020 |
| 32955174 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. | N Engl J Med | 2020 |
| 32616501 | First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. | Clin Cancer Res | 2020 |
| 32203842 | The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor. | Cancer Treat Rev | 2020 |
| 30466888 | Towards a New Classification for Metastatic Prostate Cancer. | Eur Urol | 2019 |
| 31900913 | Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer. | Adv Exp Med Biol | 2019 |
| 30119985 | Managing Nonmetastatic Castration-resistant Prostate Cancer. | Eur Urol | 2019 |
| 30257982 | RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2019 |
| 31231558 | Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making? | ESMO Open | 2019 |
| 30871108 | BRCA2 and Other DDR Genes in Prostate Cancer. | Cancers (Basel) | 2019 |
| 30954315 | PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers. | Eur Urol | 2019 |